iris has evolved

this is Pebble

portable | molecular | real-time | unique
The innovative molecular diagnostic device for rapid testing at the Point-of-Care.
pebble device

Pebble

Technology description

Pebble is a compact device for performing real-time colorimetric LAMP (qcLAMP). Pebble was created using three-dimensional (3D) additive manufacturing technology and operates via an Android application. The device can be used to extract rapidly quantitative information at a wide dynamic range of RNA or DNA template. Detection can occur from purified nucleic acids or directly from crude samples (swabs, saliva and biopsy tissue).

“Papadakis et.al, Real-time colorimetric LAMP methodology for quantitative nucleic acids detection at the point-of-care, BioRxiv 2020”

Read here

validated for :

COVID-19
and Flu A

BRAF V600E
and CYP2C19*2
mutations

Food &
plant
pathogens

key features

Sample-to-answer in 15 to 30 min

Quantitative

User-friendly

Lightweight

Battery operated

Smartphone controlled

Connected

Affordable to all

biopix-t

The company behind Pebble


Our vision

Our vision is to become an innovation leader in the field of molecular diagnostics and grow into an international company with significant global presence.

Our mission

Our mission is to offer portable diagnostic devices to every potential end-user, regardless of financial status, geographical location and training. Doctors, healthcare providers and patients in both the developed and developing countries will benefit equally from our technology, which intends to alleviate personal suffering and control disease outbreaks.

meet our team

George Papadakis, PhD

Chief Executive Officer

Alexandros Pantazis, PhD

Product Development Manager

Nikolaos Fikas, MSc

Head of Software and Electronics

Sergios Katsaros, MBA

Finance and Commercial Manager

Stella Chatziioannidou, MSc

Biotechnology R&D Specialist

Dimitra Founta, MSc

Product Development Specialist

Elena Alexandrou, MA

Operations Assistant

Angelina Barla, LL.M

Legal Advisor

Electra Gizeli, Prof.

Advisor

news

10 promising Greece-based startups to watch in 2021!

BIOPIX-T was included in the EU startups list of the 10 promising startups from Greece to watch in 2021! We are among the 10 ‘up and coming’ local startups making a name for themselves, which were founded in the last 1-3 years, show promising signs, landed funding in the last year and are growing their teams […]

read more

Quality Policy

It is the policy of BIOPIX-T to develop, manufacture and market safe and effective products to applicable specifications that meet national and International Standards and Regulatory Requirements […]

read more

Coronavirus SARS-CoV-2 Detection with IRIS

On the 21st of October 2020, the Institute of Molecular Biology and Biotechnology (IMBB) initiated the implementation of a Research Project/Programme aiming at the molecular detection of the SARS-CoV-2 virus in samples coming from volunteers-employees who show no symptoms of an active infection. The target of the research programme is to act as an additional […]

read more

BIOPIX DNA Technology P.C. receives EU funding

BIOPIX-T (www.biopix-t.com ) is pleased to announce that a consortium of eight partners in which it participated, has been awarded EU funding (€2.4M) under the emergency call H2020-SC1-PHE-CORONAVIRUS-2020-2. The aim of the proposal, entitled “Market Release of a Portable Device for COVID-19 at the Point-of-Care; a Global Diagnostics Approach” with the acronym “IRIS-COV”, is the immediate development, certification and release of BIOPIX-T ‘s novel diagnostic platform, IRIS, to carry out a combined test for SARS-CoV–2 and Influenza A.   In addition to BIOPIX-T (medical device […]

read more